[Form 4] Jazz Pharmaceuticals plc Insider Trading Activity

Rhea-AI Filing Summary

Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil reported an open-market sale of 1,200 ordinary shares on June 10, 2026 at $231.83 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan and occurred automatically. After this transaction, she directly holds 51,549 ordinary shares. A footnote also notes she acquired 123 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.

Insider Trade Summary 10b5-1

Net Seller: 1,200 shares ($278,196)

Net Sell 1 txn

Insider Patil Neena M

Role EVP & Chief Legal Officer

Sold 1,200 shs ($278K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,200	$231.83	$278K

Holdings After Transaction: Ordinary Shares — 51,549 shares (Direct, null)

Footnotes (1)

1. This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. The Reporting Person acquired 123 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.

Key Figures

Shares sold: 1,200 shares Sale price per share: $231.83 per share Shares held after transaction: 51,549 shares +1 more

4 metrics

Shares sold 1,200 shares Open-market sale on June 10, 2026

Sale price per share $231.83 per share Ordinary shares sold June 10, 2026

Shares held after transaction 51,549 shares Direct ownership following June 10, 2026 sale

ESPP acquisition 123 shares Acquired under Section 423 Employee Stock Purchase Plan on May 29, 2026

Key Terms

Rule 10b5-1, Section 423 Employee Stock Purchase Plan, open-market sale

3 terms

Rule 10b5-1 regulatory

"This transaction was made pursuant to a plan adopted ... in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Section 423 Employee Stock Purchase Plan financial

"The Reporting Person acquired 123 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026"

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 04:15 PM Accepted by SEC EDGAR 06/12/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patil Neena M

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/10/2026		S(1)		1,200	D	$231.83	51,549(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

2. The Reporting Person acquired 123 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.

	By: /s/Paz Dizon, as attorney in fact For: Neena M. Patil	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)